BDSX logo

BDSXBiodesix Inc

$15.06
$0.26
(1.76%)
Today
Closed $15.06
$0.00
(0.00%)
After Hours
Updated: 04:10 PM EDT
EarningsAug 6
Mkt Cap$153.27M
Vol21,089.00
News
all
press releases
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19
OGN's TOFIDENCE gains FDA approval for life-threatening CRS and certain hospitalized COVID-19 patients, broadening its critical-care role.
Zacks
News Placeholder
More News
News Placeholder
Humana Closes the Kindred Chapter With $900 Million Gentiva Exit
HUM is cashing out its Gentiva stake for $900 million, completing a multiyear effort to sharpen focus on its core health insurance business.
Zacks
News Placeholder
Hinge Health Expands HingeSelect to Offer End-to-End MSK Surgical Care
HNGE expands HingeSelect to include orthopedic surgery, aiming to deliver coordinated end-to-end MSK care from imaging to post-op recovery.
Zacks
News Placeholder
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
NPCE rides strong RNS adoption and AI tools nearing FDA review, with a mid-2026 IGE decision offering upside despite near-term losses.
Zacks
News Placeholder
AMN Expands Language Services Portfolio With Jaide Health Deal
AMN Healthcare acquires Jaide Health to add AI-powered interpretation and translation, widening language access across more healthcare touchpoints.
Zacks
News Placeholder
Brookdale Senior May 2026 Occupancy Volume Rises to 82.5%
BKD's occupancy climbs to 82.5% in May, extending a four-quarter growth streak and supporting its 2026 revenue and EBITDA outlook.
Zacks
News Placeholder
Zacks Industry Outlook Highlights BrightSpring Health Services, Biodesix and HealthEquity
BTSG, BDSX and HQY are positioned to benefit as digital health, analytics and patient-focused care reshape medical services.
Zacks
News Placeholder
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
MMSI leans on therapeutic strength, an oncology acquisition and a new stent launch, but tariffs, OEM weakness and China pressure shadow 2026.
Zacks
News Placeholder
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC
Natera teams with CytoDyn to track ctDNA in CLOVER Phase 2, using Signatera to map leronlimab response in metastatic colorectal cancer.
Zacks
News Placeholder
3 Medical Service Industry Stocks Thriving Amid Workforce Challenges
BTSG, BDSX and HQY stand to benefit as digital health, healthcare analytics and nursing care growth offset workforce strains.
Zacks
<
1
2
...
>

Advertisement|Remove ads.